Traphaco High Tech JSC

Traphaco High Tech JSC maintains a strong liquidity position with a current ratio of 1.36 and a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company holds VND 57,972,166,060 in cash and equivalents, which is a significant portion of its total assets of VND 445,216,127,400. This liquidity provides flexibility for operations and capital expenditures, which amounted to VND 52,328,228,720 in the latest period. The company's profitability is robust, with a return on equity (ROE) of 17.49% and a return on assets (ROA) of 8.36%. These figures exceed the typical thresholds for the pharmaceutical industry, suggesting efficient use of equity and assets to generate returns. The net income of VND 37,223,735,610 and operating income of VND 47,068,097,040 further support the company's strong earnings performance. Traphaco High Tech JSC's revenue is concentrated in a single business segment focused on herbal medicine and botanical pharmaceutical products. The company's geographic exposure is primarily within Vietnam, with no disclosed international revenue streams. This concentration may limit diversification benefits but aligns with the domestic demand for traditional medicine. The company's growth trajectory is supported by its strong operating cash flow of VND 63,322,015,540 and a revenue of VND 523,387,829,440. While the free cash flow is negative at VND -9,619,274,870, this is largely due to significant capital expenditures. The outlook for the current fiscal year and the next fiscal year remains positive, with no immediate filing-based liquidity or dilution flags detected. The risk assessment for Traphaco High Tech JSC indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is low. The absence of long-term debt and the strong cash position further mitigate financial risks. The company's capital structure is stable, with total liabilities of VND 232,418,702,790 and total equity of VND 212,797,424,610. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company continues to focus on its core business of manufacturing herbal medicine and botanical pharmaceutical products. There are no disclosed regulatory or geopolitical risks that would significantly impact the company's operations in the near term.